Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Rapamycin for Skin Aging and Epigenetic Clock
NCT04608448Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in aging comparing Topical Rapamycin with Placebo (2 arms). Primary endpoint: Change in Epigenetic Markers at 24 weeks. Started Apr 2021; status: completed.
02
Drugs
sirolimus
03
Conditions
aging
Beyond the preview
Go deeper on NCT04608448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04608448.